<SEC-DOCUMENT>0001615219-25-000069.txt : 20250714
<SEC-HEADER>0001615219-25-000069.hdr.sgml : 20250714
<ACCEPTANCE-DATETIME>20250714083335
ACCESSION NUMBER:		0001615219-25-000069
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250710
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250714
DATE AS OF CHANGE:		20250714

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Salarius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001615219
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				465087339
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36812
		FILM NUMBER:		251120214

	BUSINESS ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021
		BUSINESS PHONE:		346-772-0346

	MAIL ADDRESS:	
		STREET 1:		2450 HOLCOMBE BLVD
		STREET 2:		SUITE J-608
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Flex Pharma, Inc.
		DATE OF NAME CHANGE:	20140730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>flks-20250710.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:eeffd970-1368-493e-a4ca-d15a1acfcaad,g:6146c2d5-21cd-4a02-8422-67feba0edaf4,d:350abe36c0f34aa391cac833ae86c134-->
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>flks-20250710</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001615219</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-22">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="flks-20250710.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001615219</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-27</xbrli:startDate><xbrli:endDate>2024-09-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i350abe36c0f34aa391cac833ae86c134_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:0.05pt;margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-bottom:0.05pt;margin-top:0.05pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C.&#160; 20549</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT<br/>Pursuant to Section 13 or 15(d) of the<br/>Securities Exchange Act of 1934</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">July 10, 2025</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">SALARIUS PHARMACEUTICALS, INC.</ix:nonNumeric> <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.925%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.241%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.217%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.065%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36812</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">46-5087339</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(State or other jurisdiction of incorporation)</span></td><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(IRS Employer Identification Number)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.05pt;margin-top:0.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">2450 Holcombe Blvd.</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-8">Suite X</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-9">Houston</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-10">TX</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-11">77021</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7.5pt;font-weight:700;line-height:120%">(Zip Code)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-12">713</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-13">913-5608</ix:nonNumeric><br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">N/A <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">(Former name or former address, if changed since last report)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Title of each class</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Trading Symbol(s)</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:115%">Name of each exchange on which registered</span></div><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.0001</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">SLRX</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">The Nasdaq Capital Market</span></div></td></tr></table></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">  </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Emerging growth company </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9744;</span></div><div style="height:78.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:10pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div><div style="margin-bottom:12pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 8.01. Other Events</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">On July 10, 2025, Salarius Pharmaceuticals, Inc. (&#8220;Salarius&#8221;) received notification from The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) that the Nasdaq Hearings Panel (the &#8220;Hearings Panel&#8221;) has granted Salarius an additional extension to regain compliance with Nasdaq Listing Rule 5550(b)(1) (the &#8220;Equity Standard&#8221;) by late July 2025. Salarius must also regain compliance with Nasdaq Listing Rule 5550(a)(2) (the &#8220;Minimum Bid Price Requirement&#8221;) by early August 2025.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As previously disclosed, on April 23, 2025, Salarius received written notice (the &#8220;Delisting Notice&#8221;) from Nasdaq notifying Salarius that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of Salarius&#8217; common stock for the last 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share. Normally, a company would have been afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), Salarius was not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) because Salarius had effected a reverse stock split during the prior one-year period. In addition, as previously disclosed, on March 26, 2025, Salarius received a letter from Nasdaq notifying Salarius that, based on its Form 10-K for the year ended December 31, 2024, Salarius no longer complied with the Equity Standard. The letter indicated that Salarius had until May 12, 2025, to either regain compliance with the Equity Standard or submit a plan to Nasdaq to regain compliance with the Equity Standard (a &#8220;Compliance Plan&#8221;). However, pursuant to Nasdaq Listing Rule 5810(d)(2), Salarius&#8217; failure to comply with the Minimum Bid Price Requirement served as a separate and additional reason for delisting and, as such, the Delisting Notice indicated that Nasdaq would not entertain a Compliance Plan, and that it should address Salarius&#8217; noncompliance with the Equity Standard before the Hearings Panel </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">if Salarius appealed Nasdaq&#8217;s determination.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Salarius timely exercised its right to request a hearing, which stayed any suspension or delisting action pending the conclusion of the hearing process. On June 11, 2025, the Hearings Panel granted Salarius an extension to regain compliance with the Equity Standard and the Minimum Bid Price Requirement. The extension by the Hearings Panel is contingent on Salarius achieving scheduled milestones and notifying Nasdaq of such achievements. Such milestones initially consisted of regaining compliance with the Equity Standard by early July 2025, and regaining compliance with the Minimum Bid Price Requirement by early August 2025. The deadline for regaining compliance with the Equity Standard has now been extended to late July 2025. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Item 9.01 Financial Statements and Exhibits.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(d)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Exhibits</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:1.0%"/><td style="width:11.852%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.357%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.644%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:112%">Exhibit No.</span></div></td><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:112%">Description</span></div></td></tr><tr style="height:3pt"><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">99.1</span></div></td><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a071425slrxnasdaqfurtherex.htm">Press Release of Salarius Pharmaceuticals, Inc., dated J</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a071425slrxnasdaqfurtherex.htm">uly</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a071425slrxnasdaqfurtherex.htm"> 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a071425slrxnasdaqfurtherex.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a071425slrxnasdaqfurtherex.htm">, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a071425slrxnasdaqfurtherex.htm">5</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">104</span></div></td><td colspan="9" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Cover Page Interactive Data File (embedded within the inline XBRL document)</span></div></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:78.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div></div><div id="i350abe36c0f34aa391cac833ae86c134_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.250%"><tr><td style="width:1.0%"/><td style="width:12.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.319%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.326%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:0 1pt"/><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">SALARIUS PHARMACEUTICALS, INC.</span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"/><td colspan="18" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Date:  July 14, 2025</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">By:</span></div></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">/s/ Mark J. Rosenblum</span></div></td></tr><tr><td colspan="9" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="12" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Mark J. Rosenblum</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Executive Vice President &amp; Chief Financial Officer</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%"> </span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a071425slrxnasdaqfurtherex.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id56c55e5a4e94399aaaa25c5b1c5c39c_1"></div><div style="min-height:100.8pt;width:100%"><div><img alt="image_0.jpg" src="image_0.jpg" style="height:86px;margin-bottom:5pt;vertical-align:text-bottom;width:216px"></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq&#8217;s Stockholders&#8217; Equity Standard</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HOUSTON (July 14, 2025) &#8211; Salarius Pharmaceuticals, Inc. (Nasdaq&#58; SLRX)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (Salarius or the Company) announces that on July 10, 2025 the Company received notification from The Nasdaq Stock Market LLC (Nasdaq) of an additional extension to regain compliance with Nasdaq Listing Rule 5550(b)(1) (Equity Standard) by late July 2025. As previously disclosed, Salarius must also regain compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement) by early August 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On April 23, 2025, Salarius was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of Salarius&#8217; common stock for the prior 30 consecutive business days was lower than the minimum bid price requirement of $1.00 per share. On March 26, 2025, Nasdaq notified the Company that it no longer complied with the requirement under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders&#8217; equity for continued listing on The Nasdaq Stock Market. On June 16, 2025, Salarius disclosed that the Nasdaq Hearings Panel had granted an extension contingent on Salarius achieving milestones that consist of regaining compliance with the Equity Standard by early July 2025, and regaining compliance with the Minimum Bid Price Requirement by early August 2025.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On January 13, 2025, Salarius announced entry into a definitive merger agreement for a business combination with Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics. Under the definitive agreement announced on January 13, 2025, Decoy will merge with a wholly owned subsidiary of Salarius, subject to the closing conditions set forth in the agreement. The newly formed company will be named Decoy Therapeutics. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About the Planned Merger </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The proposed transaction, if consummated, is expected to facilitate multiple value-creating inflection points with Decoy&#8217;s pipeline of peptide conjugate therapeutics engineered by its IMP</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ACT platform, which allows for the rapid computational design and manufacturing of innovative peptide conjugate therapeutics. Decoy&#8217;s product pipeline targets unmet needs in respiratory infectious diseases and gastroenterology (GI) oncology indications. In addition to advancing the development of Decoy&#8217;s IMP</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ACT platform, the combined company intends to incorporate Salarius&#8217; oral small molecule protein degrader SP-3164 into a highly targeted peptide-based proteolysis targeting chimeras (PROTACS) drug candidate.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The combined company will be led by Decoy&#8217;s Co-founders, Chief Executive Officer Frederick &#8220;Rick&#8221; Pierce and Chief Scientific Officer Barbara Hibner, by Decoy&#8217;s Chief Business Officer Peter Marschel, Chief Technology Officer Mike Lipp, by acting Chief Medical Officer and Scientific Advisory Board Chair Shahin Gharakhanian, M.D. and by Salarius&#8217; Chief Financial Officer Mark Rosenblum. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the next 12 months, Decoy expects to advance its lead asset, a pan-coronavirus antiviral, to the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), and to make progress with its other programs including a broad-acting antiviral against flu, COVID-19 and respiratory syncytial virus (RSV), and a peptide drug conjugate targeting GI cancers. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Also during this time, data may be reported from an investigator-initiated Phase 1&#47;2 clinical study at MD Anderson Cancer Center evaluating Salarius&#8217; seclidemstat as a potential treatment for myelodysplastic syndrome and chronic myelomonocytic leukemia in patients with limited treatment options.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Decoy Therapeutics, Inc. </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Decoy Therapeutics is a preclinical-stage biotechnology company that is leveraging machine learning and artificial intelligence tools alongside high-speed synthesis techniques to rapidly design, engineer and manufacture peptide conjugate drug candidates that target serious unmet medical needs.  The company&#8217;s initial pipeline is focused on respiratory viruses and GI cancers. Decoy has attracted financing from institutional investors as well as significant non-dilutive capital from the Massachusetts Life Sciences Seed Fund, the Google AI startup program and the NVIDIA Inception program among other sources. The company has also received QuickFire Challenge award funding provided by the Biomedical Advanced Research and Development Authority (BARDA) through BLUE KNIGHT&#8482;, a collaboration between Johnson &#38; Johnson Innovation &#8211; JLABS and BARDA within the Administration for Strategic Preparedness and Response. For more information, please visit </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.DecoyTx.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Salarius Pharmaceuticals </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Salarius Pharmaceuticals&#8239;is a clinical-stage biopharmaceutical company with two drug candidates for patients with cancer in need of new treatment options. Salarius&#8217; product portfolio includes seclidemstat, the company&#8217;s lead candidate, which is being studied in an investigator-initiated Phase 1&#47;2 clinical study in hematologic cancers underway at MD Anderson Cancer Center as a potential treatment for MDS) and chronic myelomonocytic leukemia (CMML) in patients with limited treatment options. SP-3164, the company&#8217;s IND-stage second asset, is an oral small molecule protein degrader. Salarius previously received financial support for seclidemstat for the treatment of Ewing sarcoma from the National Pediatric Cancer Foundation and was a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit&#8239;www.salariuspharma.com. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About the Proposed Transaction  </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Definitive agreements were executed with unanimous approvals by the Boards of Directors of Salarius and Decoy. The closing consideration will consist primarily of nonvoting preferred stock of Salarius, and it is expected that following closing and a post-closing stockholder vote to approve the conversion of the preferred shares into common stock, Decoy investors would own approximately 92.4% of the outstanding shares of the merged company and Salarius stockholders would own approximately 7.6% of the outstanding shares, in each case exclusive of any shares issued in any financing, including the qualifying financing(s) necessary to consummate the merger transaction. For further details on the transaction and conditions for closing of the merger, please refer to the Form 8-Ks Salarius filed with the U.S. Securities and Exchange Commission (SEC) on each of January 13, 2025, March 8, 2025 and June 11, 2025 at </font><font style="color:#0563c1;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">www.sec.gov</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Non-Solicitation  </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No public offer of securities in connection with the merger shall </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:100.8pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward-Looking Statements   </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995 regarding Salarius, Decoy, the proposed merger, Salarius&#8217; ability to regain compliance with the Nasdaq continued listing requirements and other matters, including without limitation, statements relating to plans and expectations relating to the business, scientific advisory board, products, including expected achievement of milestones for its lead asset and future prospects of Salarius, Decoy and the combined company. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Salarius, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;likely,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation&#58; the risk that the conditions to the closing are not satisfied, including uncertainties as to the timing of the consummation of the proposed merger&#59; the ability of each of Salarius and Decoy to consummate the merger&#59; risks and uncertainties related to Salarius&#8217; ability to regain compliance with the Nasdaq continued listing standards in the requirement timeframe&#59; risks related to the combined company&#8217;s ability to satisfy the initial listing standards in the required timeframe&#59; Salarius may not receive any additional extensions from Nasdaq if Salarius is unable to regain compliance within the required timeframe&#59; risks related to Salarius&#8217; ability to estimate and manage its operating expenses and its expenses associated with the proposed merger pending the closing&#59; risks that the combined company will not achieve the synergies expected from the proposed merger&#59; risks that Salarius and the combined company will not obtain sufficient financing to execute on their business plans and risks related to Decoy&#8217;s products and development plans, including unanticipated issues with any IND application process and the potential of the IMP</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ACT&#8482; platform. Readers are urged to carefully review and consider the various disclosures made by Salarius in its reports filed with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as revised or supplemented by its Quarterly Reports on Form 10-Q and other documents filed with the SEC. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, Salarius&#8217; actual results may vary materially from those expected or projected.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONTACT&#58; </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Alliance Advisors IR </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Jody Cain </font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">jcain&#64;allianceadvisors.com</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">310-691-7100 </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">#  #  #</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>flks-20250710.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:eeffd970-1368-493e-a4ca-d15a1acfcaad,g:6146c2d5-21cd-4a02-8422-67feba0edaf4-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:flks="http://www.flex-pharma.com/20250710" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.flex-pharma.com/20250710">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20250710_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="flks-20250710_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.flex-pharma.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>flks-20250710_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:eeffd970-1368-493e-a4ca-d15a1acfcaad,g:6146c2d5-21cd-4a02-8422-67feba0edaf4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f41a2734-9f7e-42ff-92cb-94ad747615d4_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_13a0174d-7eea-4d56-bae3-49c7b738ed77_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3fc01b0b-a92b-4711-8a78-8dcd37037e9e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4d7cbbbf-aa13-4d12-a7dc-90b0512390a6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_ee14d9df-ef54-46de-829d-96c996370713_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_593be81e-cd88-4079-b48f-339298fa7c3b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_258f54da-cf14-4b0e-b014-3b1d64f1a9b8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_865b6d1d-663a-4806-9d73-b77a4f093b80_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b72495af-1d4b-4626-a24d-06ea7eec5f6c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_0be5e014-745e-43d9-b520-ff2c68b28f32_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_50f295f0-9bb1-41d0-a823-d77808802459_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6b662367-ec2e-46e5-a495-2c08972c2f53_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e28d464d-5f06-440f-b2fa-44373da56c67_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4b62f09b-33d1-43ab-8335-a0871fcd0413_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_10d3f5a9-2c7a-4094-bbbc-6ee0f3a44fbc_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_09d63758-dff6-4628-89b8-a8df7b1ed77c_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8da502d4-1250-4432-9ab6-f9235d3ee911_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_be0bbfa4-5768-4c10-bc33-49e0153e45b0_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4af69054-139c-4080-9a3d-c697675eb66a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_aac30b86-d8ac-4af1-be3b-6fc02bdac85d_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_deb5e265-6ef1-40ee-8362-23ac0cc07339_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b9206a77-5309-47a5-8947-11a545f8d5fc_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>flks-20250710_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:eeffd970-1368-493e-a4ca-d15a1acfcaad,g:6146c2d5-21cd-4a02-8422-67feba0edaf4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.flex-pharma.com/role/CoverPage" xlink:type="simple" xlink:href="flks-20250710.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.flex-pharma.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_627a4c89-8658-46e7-a038-0bed5db9940b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_DocumentType_627a4c89-8658-46e7-a038-0bed5db9940b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8cce9996-3f75-4b69-976f-af8372694edf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_DocumentPeriodEndDate_8cce9996-3f75-4b69-976f-af8372694edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9c3d2f67-4b41-4ec6-8b25-09b4ff2b7c5f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_EntityRegistrantName_9c3d2f67-4b41-4ec6-8b25-09b4ff2b7c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_2e1853a5-a507-4c1e-a06b-1f269c1702c2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_2e1853a5-a507-4c1e-a06b-1f269c1702c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3b8cc1b6-1dec-404f-ad81-4c91d5cda418" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_EntityFileNumber_3b8cc1b6-1dec-404f-ad81-4c91d5cda418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_15040b0d-403a-43ba-9fc9-33d43cf7f694" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_EntityTaxIdentificationNumber_15040b0d-403a-43ba-9fc9-33d43cf7f694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_14e8f0fd-8477-4bfc-8ab7-caf9e0254d38" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_EntityAddressAddressLine2_14e8f0fd-8477-4bfc-8ab7-caf9e0254d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_7624baac-a3ed-4d70-9a88-30a57c7597bf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_EntityAddressAddressLine1_7624baac-a3ed-4d70-9a88-30a57c7597bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1b88f7f6-d7a2-4c04-981e-9c6bf2d2245d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_EntityAddressCityOrTown_1b88f7f6-d7a2-4c04-981e-9c6bf2d2245d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c760651c-7fe5-4bc0-8124-5621ef20bfca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_EntityAddressStateOrProvince_c760651c-7fe5-4bc0-8124-5621ef20bfca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d9c703bc-78b6-4253-ab75-40f706ea0382" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_EntityAddressPostalZipCode_d9c703bc-78b6-4253-ab75-40f706ea0382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_98c06bcf-b883-4c56-b210-3c635e266b1c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_CityAreaCode_98c06bcf-b883-4c56-b210-3c635e266b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_87235a8d-b45d-4e32-a9d6-91553f11e03b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_LocalPhoneNumber_87235a8d-b45d-4e32-a9d6-91553f11e03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_43e2d254-9282-49f6-b03b-917948742526" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_WrittenCommunications_43e2d254-9282-49f6-b03b-917948742526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_18bb4792-3ca0-4124-9398-a1609167fc0d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_SolicitingMaterial_18bb4792-3ca0-4124-9398-a1609167fc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_7aaafbcb-6ac9-4124-adce-b6bfe2175856" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_PreCommencementTenderOffer_7aaafbcb-6ac9-4124-adce-b6bfe2175856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_acc64f29-9a28-44d5-b5a4-6dd0e7ddde52" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_acc64f29-9a28-44d5-b5a4-6dd0e7ddde52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ce90f286-c37d-49c0-9d14-1c5648d86a03" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_Security12bTitle_ce90f286-c37d-49c0-9d14-1c5648d86a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e70070ad-66cc-4645-9f18-8840c5a7adb4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_TradingSymbol_e70070ad-66cc-4645-9f18-8840c5a7adb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ea115a90-3aba-4e08-9888-4d40fbdbebea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_EntityEmergingGrowthCompany_ea115a90-3aba-4e08-9888-4d40fbdbebea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0edfaf50-cb94-4e9c-b4c1-964c2217458d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_EntityCentralIndexKey_0edfaf50-cb94-4e9c-b4c1-964c2217458d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b74b874a-6a21-4c0e-8a63-758334a2b905" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_90801175-013d-44ae-92e7-40f98cb89b7d" xlink:to="loc_dei_AmendmentFlag_b74b874a-6a21-4c0e-8a63-758334a2b905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@   ?0   #(" 8    >&1/H   I^TE$051XVNV=
M"9@4Q?G&V=T16(*(!Z+<("IJ('@!WB*&@"=$PR$>B*B$:,3EB">BB!B,LAYX
M$%1$6<0K> 7CK2!*O!#01#'"J@BH( AR"O/_*G[[3U'VS%155_5T[[SO\[Q/
M##M575W=7;^NZJJO:J0:E=6O 4$0!$%0L@6@0Q $05#U 'I3U ($01 $)1_H
M[5$+$ 1!$)1\H'=#+4 0!$%0\H%^(6H!@B (@I(/])M0"Q $01"4?* _BUJ
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M/(&!4<;5@""7#_<>F@VU*]^MNR:;()TBOZX!\\B KM1=$_(?>1_SC9[K[5P
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ME6?)@WAT[Q .JC2$M_.UV4.B/$<9N_+HE,Y.:6?DVN.<1]<ZD]_1+)_XE-<
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MV070>;3@"VD9T!XYKL\D !U 3S+0N;.Y3 HVM%N.Y^[V$,>*,K!,[PR1]43
MM?.U \=DR/P4AS!O7B/&(G!/SA#+?9-/H--O#U;6H3]KD':)$B_=)M[S^K!
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M?J<Q26EIR!V>M!HVWII1[C&7AJSKU;G JXP^J/-(2ET#/2 $I\Z6FG(L^P4
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$KD)@@@$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>Sep. 27, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 10,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SALARIUS PHARMACEUTICALS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5087339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite X<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2450 Holcombe Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Houston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">913-5608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SLRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001615219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="flks-20250710.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.flex-pharma.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="flks-20250710.htm">flks-20250710.htm</File>
    <File>flks-20250710.xsd</File>
    <File>flks-20250710_lab.xml</File>
    <File>flks-20250710_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "flks-20250710.htm": {
   "nsprefix": "flks",
   "nsuri": "http://www.flex-pharma.com/20250710",
   "dts": {
    "inline": {
     "local": [
      "flks-20250710.htm"
     ]
    },
    "schema": {
     "local": [
      "flks-20250710.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "flks-20250710_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "flks-20250710_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.flex-pharma.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "flks-20250710.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "flks-20250710.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.flex-pharma.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001615219-25-000069-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001615219-25-000069-xbrl.zip
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MRVX4*"L4^4<F2LD"AP^J,1W%=#T)M5^O,1\S,<@+G8C=/:<(+5[-I/4: %7
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M^_:4.BF.D3AZM3_LAD4._5P5;>2&*/KAR5.$LH@[O;&9/@Z,?<K^_0H)YRT
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M($ AMY+YY]$5<TY+E@);[=$ICL1X9^#!=(L^4!=2=^C9;/X;6Y0(MT]+#@A
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M&#^-Z=23DTX^+[EHJ:754B OGKO-A:W;)]*6QFYM=:G$ZZO\Q\Q$,I81J0Y
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M$#0.:1@H3BFS*V!M@6GJUI.F5XG:5JMG<S*T2+D[=:I-0TTZ5*1N)R,*T;.
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M;-5:;5/<.!+^SJ^8F_MZ8B19EB4JL,6QR15U[(9*V-JM^^+22VO&%8\])9L
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MP6,'GG5[9'!$&9L19X(&[ 2%3Z;(%4^H'D2.;.[D&(OI3(G!\DQR88UQQ"2
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MH[W_ U!+ 0(4 Q0    ( #%$[EI 2W/>]1(  "U$   >              "
M 0    !A,#<Q-#(U<VQR>&YA<V1A<69U<G1H97)E>"YH=&U02P$"% ,4
M"  Q1.Y:=:-=*J42  #!?P  $0              @ $Q$P  9FQK<RTR,#(U
M,#<Q,"YH=&U02P$"% ,4    "  Q1.Y:=E]M)&8"   /!P  $0
M    @ $%)@  9FQK<RTR,#(U,#<Q,"YX<V102P$"% ,4    "  Q1.Y:KDAR
M%?L)  "Y5   %0              @ &:*   9FQK<RTR,#(U,#<Q,%]L86(N
M>&UL4$L! A0#%     @ ,43N6I#LB0RQ!@  _S   !4              ( !
MR#(  &9L:W,M,C R-3 W,3!?<')E+GAM;%!+!08     !0 % % !  "L.0
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>flks-20250710_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="flks-20250710.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001615219</identifier>
        </entity>
        <period>
            <startDate>2024-09-27</startDate>
            <endDate>2024-09-27</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001615219</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-07-10</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">SALARIUS PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36812</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">46-5087339</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">2450 Holcombe Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-8">Suite X</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-9">Houston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-10">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-11">77021</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-12">713</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-13">913-5608</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-14">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-15">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">SLRX</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
